By Ian Copper
Earlier this week, shares of Fate Therapeutics (FATE) closed at $20.41, flat from the prior trading day. The biotech stock is up nearly 74% from a low of $11.70 set in January 2019. That’s more than triple the return of the iShares NASDAQ Biotechnology ETF (IBB), and the S&P 500’s gain of 27% on the year. Wall Street is looking for further strength from the company, given its strong pipeline of drug treatments.